277 related articles for article (PubMed ID: 24682000)
1. An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children.
Dave UP; Dingankar SR; Saxena VS; Joseph JA; Bethapudi B; Agarwal A; Kudiganti V
Adv Mind Body Med; 2014; 28(2):10-5. PubMed ID: 24682000
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI 08) on Hyperactivity and Inattention in Male Children and Adolescents: BACHI Study Protocol (ANZCTRN12612000827831).
Kean JD; Kaufman J; Lomas J; Goh A; White D; Simpson D; Scholey A; Singh H; Sarris J; Zangara A; Stough C
Nutrients; 2015 Dec; 7(12):9931-45. PubMed ID: 26633481
[TBL] [Abstract][Full Text] [Related]
4. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Boellner SW; Earl CQ; Arora S
Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
8. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
10. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study.
Lyon MR; Cline JC; Totosy de Zepetnek J; Shan JJ; Pang P; Benishin C
J Psychiatry Neurosci; 2001 May; 26(3):221-8. PubMed ID: 11394191
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
12. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
13. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
14. Posttraumatic stress disorder in adult attention-deficit/hyperactivity disorder: clinical features and familial transmission.
Antshel KM; Kaul P; Biederman J; Spencer TJ; Hier BO; Hendricks K; Faraone SV
J Clin Psychiatry; 2013 Mar; 74(3):e197-204. PubMed ID: 23561240
[TBL] [Abstract][Full Text] [Related]
15. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
16. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
17. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
[TBL] [Abstract][Full Text] [Related]
18. Effects of Korean red ginseng extract on behavior in children with symptoms of inattention and hyperactivity/impulsivity: a double-blind randomized placebo-controlled trial.
Ko HJ; Kim I; Kim JB; Moon Y; Whang MC; Lee KM; Jung SP
J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):501-8. PubMed ID: 25369174
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
[TBL] [Abstract][Full Text] [Related]
20. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
Sumner CR; Haynes VS; Teicher MH; Newcorn JH
Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
